Integrated Stability and Metabolomic Investigation of New Rifampicin and Isoniazid co-loaded Liposome against Tuberculosis Article Swipe
Pranay Sinha
,
Vinod L. Gaikwad
,
Debabrata Mandal
,
E. Bhargav
,
Rahul L. Gajbhiye
,
Ramalingam Peraman
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-7913588/v1
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.21203/rs.3.rs-7913588/v1
This study aimed to develop and evaluate rifampicin (RIF) and isoniazid (INH) co-loaded liposome for sustained drug delivery to enhance therapeutic efficacy against tuberculosis (TB) and overcome challenges associated with prolonged treatment and drug resistance. A novel biocompatible liposomal system that enables sustained co-delivery of RIF and INH, thereby enhancing therapeutic efficacy and reducing drug resistance in TB treatment. However, the formulation offers a stable and scalable delivery platform with sustained release, improved antimicrobial efficacy, and significant potential for advancing tuberculosis therapy. Liposome were prepared using soybean lecithin and cholesterol (L-CH) via rotary evaporator-assisted thin film hydration, optimized by Box–Behnken design, and characterized for size, PDI, entrapment efficiency, and physicochemical properties (FT-IR, DSC, HR-TEM). In vitro release, accelerated stability, antimicrobial efficacy against M. smegmatis and M. tuberculosis H 37 Rv, and LC-MS/MS-based metabolomic profiling were systematically evaluated. The optimised liposome exhibited a mean size of 129.5 ± 2.20 nm, PDI of 0.369 ± 0.06, and entrapment efficiencies of 63.84 ± 1.62% (RIF) and 56.92 ± 1.69% (INH). Following Higuchi diffusion-controlled kinetics, sustained release was observed, with INH (~ 92%) and RIF (~ 85%) over 45 hours. Accelerated stability studies showed minimal drug degradation. Antimicrobial assays revealed a twofold reduction in minimum inhibitory concentration compared to free drugs. Metabolomic analysis demonstrated modulation of glutathione, citric acid, and tyrosine pathways, suggesting improved redox balance and antimicrobial effect. The co-loaded RIF–INH liposomal system offers a promising, clinically translatable approach for sustained drug release and improved tuberculosis therapy.
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Landing Page
- https://doi.org/10.21203/rs.3.rs-7913588/v1
- https://www.researchsquare.com/article/rs-7913588/latest.pdf
- OA Status
- gold
- References
- 44
- OpenAlex ID
- https://openalex.org/W4415935500
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4415935500Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.21203/rs.3.rs-7913588/v1Digital Object Identifier
- Title
-
Integrated Stability and Metabolomic Investigation of New Rifampicin and Isoniazid co-loaded Liposome against TuberculosisWork title
- Type
-
articleOpenAlex work type
- Publication year
-
2025Year of publication
- Publication date
-
2025-11-05Full publication date if available
- Authors
-
Pranay Sinha, Vinod L. Gaikwad, Debabrata Mandal, E. Bhargav, Rahul L. Gajbhiye, Ramalingam PeramanList of authors in order
- Landing page
-
https://doi.org/10.21203/rs.3.rs-7913588/v1Publisher landing page
- PDF URL
-
https://www.researchsquare.com/article/rs-7913588/latest.pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://www.researchsquare.com/article/rs-7913588/latest.pdfDirect OA link when available
- Cited by
-
0Total citation count in OpenAlex
- References (count)
-
44Number of works referenced by this work
Full payload
| id | https://openalex.org/W4415935500 |
|---|---|
| doi | https://doi.org/10.21203/rs.3.rs-7913588/v1 |
| ids.doi | https://doi.org/10.21203/rs.3.rs-7913588/v1 |
| ids.openalex | https://openalex.org/W4415935500 |
| fwci | 0.0 |
| type | article |
| title | Integrated Stability and Metabolomic Investigation of New Rifampicin and Isoniazid co-loaded Liposome against Tuberculosis |
| biblio.issue | |
| biblio.volume | |
| biblio.last_page | |
| biblio.first_page | |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| language | |
| locations[0].id | doi:10.21203/rs.3.rs-7913588/v1 |
| locations[0].is_oa | True |
| locations[0].source | |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.researchsquare.com/article/rs-7913588/latest.pdf |
| locations[0].version | acceptedVersion |
| locations[0].raw_type | posted-content |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | False |
| locations[0].raw_source_name | |
| locations[0].landing_page_url | https://doi.org/10.21203/rs.3.rs-7913588/v1 |
| indexed_in | crossref |
| authorships[0].author.id | https://openalex.org/A5036732375 |
| authorships[0].author.orcid | https://orcid.org/0000-0002-4233-0871 |
| authorships[0].author.display_name | Pranay Sinha |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | PRAGATI SINHA |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5014313590 |
| authorships[1].author.orcid | https://orcid.org/0000-0002-3368-4467 |
| authorships[1].author.display_name | Vinod L. Gaikwad |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Vinod L Gaikwad |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5032831718 |
| authorships[2].author.orcid | https://orcid.org/0000-0001-6413-8509 |
| authorships[2].author.display_name | Debabrata Mandal |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Debabrata Mandal |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5049731455 |
| authorships[3].author.orcid | https://orcid.org/0000-0001-7799-4427 |
| authorships[3].author.display_name | E. Bhargav |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | E Bhargav |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5022787203 |
| authorships[4].author.orcid | https://orcid.org/0000-0003-0490-1423 |
| authorships[4].author.display_name | Rahul L. Gajbhiye |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Rahul Laxman Gajbhiye |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5028799975 |
| authorships[5].author.orcid | https://orcid.org/0000-0003-1932-637X |
| authorships[5].author.display_name | Ramalingam Peraman |
| authorships[5].author_position | last |
| authorships[5].raw_author_name | Ramalingam Peraman |
| authorships[5].is_corresponding | False |
| has_content.pdf | True |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.researchsquare.com/article/rs-7913588/latest.pdf |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-11-05T00:00:00 |
| display_name | Integrated Stability and Metabolomic Investigation of New Rifampicin and Isoniazid co-loaded Liposome against Tuberculosis |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T23:17:08.748858 |
| primary_topic | |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.21203/rs.3.rs-7913588/v1 |
| best_oa_location.is_oa | True |
| best_oa_location.source | |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.researchsquare.com/article/rs-7913588/latest.pdf |
| best_oa_location.version | acceptedVersion |
| best_oa_location.raw_type | posted-content |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | False |
| best_oa_location.raw_source_name | |
| best_oa_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-7913588/v1 |
| primary_location.id | doi:10.21203/rs.3.rs-7913588/v1 |
| primary_location.is_oa | True |
| primary_location.source | |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.researchsquare.com/article/rs-7913588/latest.pdf |
| primary_location.version | acceptedVersion |
| primary_location.raw_type | posted-content |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | False |
| primary_location.raw_source_name | |
| primary_location.landing_page_url | https://doi.org/10.21203/rs.3.rs-7913588/v1 |
| publication_date | 2025-11-05 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W2994700193, https://openalex.org/W2739353534, https://openalex.org/W3036101776, https://openalex.org/W2147467826, https://openalex.org/W2003297681, https://openalex.org/W2747594576, https://openalex.org/W3107153778, https://openalex.org/W2762527716, https://openalex.org/W2068392457, https://openalex.org/W2888961376, https://openalex.org/W2097524866, https://openalex.org/W2417671150, https://openalex.org/W3131430042, https://openalex.org/W2155750714, https://openalex.org/W2612594981, https://openalex.org/W2793726466, https://openalex.org/W2157183580, https://openalex.org/W2094397842, https://openalex.org/W2104241359, https://openalex.org/W2164951692, https://openalex.org/W2337917444, https://openalex.org/W1986998462, https://openalex.org/W1689426281, https://openalex.org/W4323568211, https://openalex.org/W2942370388, https://openalex.org/W4283394718, https://openalex.org/W2934181292, https://openalex.org/W2736271411, https://openalex.org/W4308306440, https://openalex.org/W2792874817, https://openalex.org/W2115993813, https://openalex.org/W2983522680, https://openalex.org/W2064193410, https://openalex.org/W2076230956, https://openalex.org/W2945802266, https://openalex.org/W2808481523, https://openalex.org/W4220662622, https://openalex.org/W2511207864, https://openalex.org/W2889675760, https://openalex.org/W2100318947, https://openalex.org/W4403645826, https://openalex.org/W4285222191, https://openalex.org/W1987805766, https://openalex.org/W2606160688 |
| referenced_works_count | 44 |
| abstract_inverted_index.A | 36 |
| abstract_inverted_index.H | 128 |
| abstract_inverted_index.a | 64, 142, 197, 232 |
| abstract_inverted_index.(~ | 178, 182 |
| abstract_inverted_index.45 | 185 |
| abstract_inverted_index.TB | 58 |
| abstract_inverted_index.by | 99 |
| abstract_inverted_index.in | 57, 200 |
| abstract_inverted_index.of | 45, 145, 151, 158, 212 |
| abstract_inverted_index.to | 4, 19, 205 |
| abstract_inverted_index.± | 147, 153, 160, 165 |
| abstract_inverted_index.INH | 177 |
| abstract_inverted_index.PDI | 150 |
| abstract_inverted_index.RIF | 46, 181 |
| abstract_inverted_index.Rv, | 130 |
| abstract_inverted_index.The | 138, 226 |
| abstract_inverted_index.and | 6, 10, 26, 33, 47, 53, 66, 76, 89, 102, 109, 125, 131, 155, 163, 180, 216, 223, 241 |
| abstract_inverted_index.for | 15, 79, 104, 237 |
| abstract_inverted_index.nm, | 149 |
| abstract_inverted_index.the | 61 |
| abstract_inverted_index.via | 92 |
| abstract_inverted_index.was | 174 |
| abstract_inverted_index.(TB) | 25 |
| abstract_inverted_index.2.20 | 148 |
| abstract_inverted_index.85%) | 183 |
| abstract_inverted_index.92%) | 179 |
| abstract_inverted_index.DSC, | 113 |
| abstract_inverted_index.INH, | 48 |
| abstract_inverted_index.PDI, | 106 |
| abstract_inverted_index.This | 1 |
| abstract_inverted_index.drug | 17, 34, 55, 192, 239 |
| abstract_inverted_index.film | 96 |
| abstract_inverted_index.free | 206 |
| abstract_inverted_index.mean | 143 |
| abstract_inverted_index.over | 184 |
| abstract_inverted_index.size | 144 |
| abstract_inverted_index.that | 41 |
| abstract_inverted_index.thin | 95 |
| abstract_inverted_index.were | 84, 135 |
| abstract_inverted_index.with | 30, 70, 176 |
| abstract_inverted_index.(INH) | 12 |
| abstract_inverted_index.(RIF) | 9, 162 |
| abstract_inverted_index.0.06, | 154 |
| abstract_inverted_index.0.369 | 152 |
| abstract_inverted_index.1.62% | 161 |
| abstract_inverted_index.1.69% | 166 |
| abstract_inverted_index.129.5 | 146 |
| abstract_inverted_index.56.92 | 164 |
| abstract_inverted_index.63.84 | 159 |
| abstract_inverted_index.acid, | 215 |
| abstract_inverted_index.aimed | 3 |
| abstract_inverted_index.novel | 37 |
| abstract_inverted_index.redox | 221 |
| abstract_inverted_index.size, | 105 |
| abstract_inverted_index.study | 2 |
| abstract_inverted_index.using | 86 |
| abstract_inverted_index.(INH). | 167 |
| abstract_inverted_index.(L-CH) | 91 |
| abstract_inverted_index.assays | 195 |
| abstract_inverted_index.citric | 214 |
| abstract_inverted_index.drugs. | 207 |
| abstract_inverted_index.hours. | 186 |
| abstract_inverted_index.offers | 63, 231 |
| abstract_inverted_index.rotary | 93 |
| abstract_inverted_index.showed | 190 |
| abstract_inverted_index.stable | 65 |
| abstract_inverted_index.system | 40, 230 |
| abstract_inverted_index.(FT-IR, | 112 |
| abstract_inverted_index.Higuchi | 169 |
| abstract_inverted_index.against | 23, 122 |
| abstract_inverted_index.balance | 222 |
| abstract_inverted_index.design, | 101 |
| abstract_inverted_index.develop | 5 |
| abstract_inverted_index.effect. | 225 |
| abstract_inverted_index.enables | 42 |
| abstract_inverted_index.enhance | 20 |
| abstract_inverted_index.minimal | 191 |
| abstract_inverted_index.minimum | 201 |
| abstract_inverted_index.release | 173, 240 |
| abstract_inverted_index.soybean | 87 |
| abstract_inverted_index.studies | 189 |
| abstract_inverted_index.thereby | 49 |
| abstract_inverted_index.twofold | 198 |
| abstract_inverted_index.HR-TEM). | 114 |
| abstract_inverted_index.However, | 60 |
| abstract_inverted_index.Liposome | 83 |
| abstract_inverted_index.analysis | 209 |
| abstract_inverted_index.approach | 236 |
| abstract_inverted_index.compared | 204 |
| abstract_inverted_index.delivery | 18, 68 |
| abstract_inverted_index.efficacy | 22, 52, 121 |
| abstract_inverted_index.evaluate | 7 |
| abstract_inverted_index.improved | 73, 220, 242 |
| abstract_inverted_index.lecithin | 88 |
| abstract_inverted_index.liposome | 14, 140 |
| abstract_inverted_index.overcome | 27 |
| abstract_inverted_index.platform | 69 |
| abstract_inverted_index.prepared | 85 |
| abstract_inverted_index.reducing | 54 |
| abstract_inverted_index.release, | 72, 117 |
| abstract_inverted_index.revealed | 196 |
| abstract_inverted_index.scalable | 67 |
| abstract_inverted_index.therapy. | 82, 244 |
| abstract_inverted_index.tyrosine | 217 |
| abstract_inverted_index.Following | 168 |
| abstract_inverted_index.RIF–INH | 228 |
| abstract_inverted_index.advancing | 80 |
| abstract_inverted_index.co-loaded | 13, 227 |
| abstract_inverted_index.efficacy, | 75 |
| abstract_inverted_index.enhancing | 50 |
| abstract_inverted_index.exhibited | 141 |
| abstract_inverted_index.isoniazid | 11 |
| abstract_inverted_index.kinetics, | 171 |
| abstract_inverted_index.liposomal | 39, 229 |
| abstract_inverted_index.observed, | 175 |
| abstract_inverted_index.optimised | 139 |
| abstract_inverted_index.optimized | 98 |
| abstract_inverted_index.pathways, | 218 |
| abstract_inverted_index.potential | 78 |
| abstract_inverted_index.profiling | 134 |
| abstract_inverted_index.prolonged | 31 |
| abstract_inverted_index.reduction | 199 |
| abstract_inverted_index.stability | 188 |
| abstract_inverted_index.sustained | 16, 43, 71, 172, 238 |
| abstract_inverted_index.treatment | 32 |
| abstract_inverted_index.<italic>In | 115 |
| abstract_inverted_index.<italic>M. | 123, 126 |
| abstract_inverted_index.associated | 29 |
| abstract_inverted_index.challenges | 28 |
| abstract_inverted_index.clinically | 234 |
| abstract_inverted_index.entrapment | 107, 156 |
| abstract_inverted_index.evaluated. | 137 |
| abstract_inverted_index.hydration, | 97 |
| abstract_inverted_index.inhibitory | 202 |
| abstract_inverted_index.modulation | 211 |
| abstract_inverted_index.promising, | 233 |
| abstract_inverted_index.properties | 111 |
| abstract_inverted_index.resistance | 56 |
| abstract_inverted_index.rifampicin | 8 |
| abstract_inverted_index.stability, | 119 |
| abstract_inverted_index.suggesting | 219 |
| abstract_inverted_index.treatment. | 59 |
| abstract_inverted_index.Accelerated | 187 |
| abstract_inverted_index.Metabolomic | 208 |
| abstract_inverted_index.accelerated | 118 |
| abstract_inverted_index.cholesterol | 90 |
| abstract_inverted_index.co-delivery | 44 |
| abstract_inverted_index.efficiency, | 108 |
| abstract_inverted_index.formulation | 62 |
| abstract_inverted_index.metabolomic | 133 |
| abstract_inverted_index.resistance. | 35 |
| abstract_inverted_index.significant | 77 |
| abstract_inverted_index.therapeutic | 21, 51 |
| abstract_inverted_index.degradation. | 193 |
| abstract_inverted_index.demonstrated | 210 |
| abstract_inverted_index.efficiencies | 157 |
| abstract_inverted_index.glutathione, | 213 |
| abstract_inverted_index.translatable | 235 |
| abstract_inverted_index.tuberculosis | 24, 81, 243 |
| abstract_inverted_index.<sub>37</sub> | 129 |
| abstract_inverted_index.Antimicrobial | 194 |
| abstract_inverted_index.Box–Behnken | 100 |
| abstract_inverted_index.antimicrobial | 74, 120, 224 |
| abstract_inverted_index.biocompatible | 38 |
| abstract_inverted_index.characterized | 103 |
| abstract_inverted_index.concentration | 203 |
| abstract_inverted_index.LC-MS/MS-based | 132 |
| abstract_inverted_index.systematically | 136 |
| abstract_inverted_index.vitro</italic> | 116 |
| abstract_inverted_index.physicochemical | 110 |
| abstract_inverted_index.smegmatis</italic> | 124 |
| abstract_inverted_index.evaporator-assisted | 94 |
| abstract_inverted_index.diffusion-controlled | 170 |
| abstract_inverted_index.tuberculosis</italic> | 127 |
| abstract_inverted_index.<title>Abstract</title> | 0 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 6 |
| citation_normalized_percentile |